Guideline-Based Direct Medical Costs for Major Mental Disorders in the Mexican Social Security System
This study estimates that providing guideline-based care for major mental disorders within Mexico's IMSS system incurs an annual national cost of approximately USD 3.01 billion, driven primarily by the high prevalence of anxiety and depressive disorders despite schizophrenia and bipolar disorder requiring higher per-patient treatment resources.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Mental health is not just a matter of how people feel; it is a matter of how societies function and how their resources are spent. In Mexico, as in many places, conditions like anxiety, depression, schizophrenia, and bipolar disorder are among the leading causes of illness and disability. These are not fleeting moods but complex medical conditions that require ongoing care, medication, and regular visits to doctors. For the millions of people covered by the Mexican Social Security Institute, known as IMSS, the question of how to pay for this care is critical. The system must balance the needs of patients with the reality of its budget. To do this effectively, planners need to know exactly what it costs to provide the right kind of treatment. This means understanding not just the price of a single pill or a single visit, but the total price of a full year of care that follows the best medical advice available. Without these numbers, it is impossible to know if the system is prepared to handle the demand or if it is underfunding the very services that keep people healthy.
A team of researchers set out to answer this question by calculating the direct medical costs for the four most common serious mental disorders treated within the IMSS system. They focused on anxiety disorders, depressive disorders, schizophrenia, and bipolar disorder. Instead of guessing or using old data, they built their estimates from the ground up, a method that involves listing every single item a patient needs for a year of care and adding up the price of each one. They looked at the official records of more than 3.5 million patients treated in 2023. For each of the four conditions, they created a standard "recipe" for care based on international medical guidelines. This recipe included the specific medicines a patient would take, how often they would see a specialist, how often they would see a family doctor, and what blood tests they would need. They then attached the official prices for these items, using current government lists for medicine costs and hospital service fees.
The results reveal a story of two very different kinds of financial burdens. On one hand, anxiety and depression are the most common conditions, affecting millions of people. Because so many individuals have these diagnoses, the total amount of money needed to treat them is enormous. The researchers estimated that treating anxiety disorders for all patients in the system would cost about 2.65 billion US dollars in a single year. Treating depression would cost another 248 million US dollars. These high totals are driven purely by the sheer number of people who need help. On the other hand, schizophrenia and bipolar disorder affect far fewer people, but the cost to treat each individual is much higher. For a patient with schizophrenia, the estimated annual cost is roughly 1,504 US dollars, which is nearly double the cost for a patient with anxiety. This is because the treatment for schizophrenia requires more expensive medications and more intensive monitoring. Even though fewer people have schizophrenia, the total cost for the entire group still adds up to about 80.8 million US dollars. Bipolar disorder falls somewhere in between, with a per-patient cost of about 1,181 US dollars, leading to a national total of 28.9 million US dollars.
When the researchers looked at who is paying for this care, they found clear patterns based on gender and location. Women make up the majority of patients with anxiety, depression, and bipolar disorder, meaning the system spends significantly more on their care simply because there are more women seeking treatment for these conditions. Men, however, make up the majority of patients with schizophrenia, shifting the cost burden for that specific condition toward male patients. The money is not spent evenly across the country either. The highest total costs are concentrated in the northern and central regions, particularly in Mexico City and the state of Mexico, where the population is largest. However, even in less populated areas, the need for specialized care is significant, showing that the demand for mental health services is widespread.
The study also examined what makes up these costs. For anxiety and depression, the vast majority of the expense comes from doctor visits, specifically the frequent check-ins with family doctors and specialists required to keep the treatment on track. Medications make up a very small portion of the bill for these two conditions. For schizophrenia and bipolar disorder, the picture changes. While doctor visits are still a major cost, the price of medication becomes a much larger part of the total, accounting for nearly half of the cost for schizophrenia. This highlights that while frequent medical attention is the main driver of costs for common conditions, expensive drugs are a major factor for the more severe disorders. The researchers noted that their numbers represent the cost of providing ideal, guideline-based care. They did not include costs for hospital stays, emergency room visits, or the indirect costs of lost work, meaning the true financial impact on society is likely even higher than these figures suggest.
Ultimately, this work provides a clear map of where the money goes in Mexico's public mental health system. It shows that while anxiety and depression create the biggest total bill because they are so common, schizophrenia and bipolar disorder require the most resources for each individual patient. The findings suggest that planning for mental health cannot rely on a one-size-fits-all approach. Budgets must account for the high volume of patients with common conditions while also reserving enough resources to cover the intensive, expensive care needed for those with severe disorders. By knowing exactly what guideline-concordant care costs, health officials can make better decisions about how to allocate funds, ensuring that the system is ready to support the millions of people who rely on it for their mental well-being.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.